Dublin, Oct. 20, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "The Overview of Biosimilar Market in Japan ver2016" report to their offering. The reader will understand overall trend of Japanese biosimilar market. The report covers market situation, pipeline, major players, and challenges and forecast of this market. The market size for generics in 2012 was about 551 billion JPY. This was about 9% of the prescription drugs market as a whole. The generics market is estimated to grow to around 778 billion JPY in 2016. The market for biosimilars was 4.5 billion JPY in 2012. A total of only three products including human growth hormone and erythropoietin were on the market by 2012. The market is expected to reach over 26 billion JPY by 2016. Key Topics Covered: 1. Summary 2. Definition of biosimilar 3. Related Pharmaceutical Affairs 4. Market Size 5. Market Trends 6. Biosimilar Sales Items and Main Development Items (As of 2015) 7. Trends for Major Companies 8. Daiichi Sankyo 9. Nichi-Iko 10. Sanwa Kagaku 11. Mochida Pharmaceutical 12. Nippon Kayaku 13. Kissei 14. Boehringer Ingelheim 15. Future Development 16. Challenges and Forecast for Biosimilars
For more information about this report visit http://www.researchandmarkets.com/research/hb...verview_of
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Biosimilars and Biosuperiors